Search Results

Your search for Rana R. McKay, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 24th SUO Annual Meeting

Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II findings from the Neptune study of neoadjuvant olaparib plus androgen-deprivation therapy followed by radical prostatectomy in patients with intermediate-risk or high-risk prostate cancer marked by germline or somatic ...

prostate cancer

By The ASCO Post Staff / ASCO20 Virtual Scientific Program

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract...

Apr

Today In Oncology

Search Results

Your search for Rana R. McKay, MD matches 2 pages

Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer

Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer